123 filings
8-K
NAMS
NewAmsterdam Pharma Company NV
11 Jun 24
NewAmsterdam Pharma Announces Issuance of Composition of Matter Patent for Obicetrapib by the United
8:12am
8-K
NAMS
NewAmsterdam Pharma Company NV
7 Jun 24
Submission of Matters to a Vote of Security Holders
4:15pm
ARS
2023 FY
NAMS
NewAmsterdam Pharma Company NV
9 May 24
Annual report to shareholders
4:18pm
DEF 14A
NAMS
NewAmsterdam Pharma Company NV
9 May 24
Definitive proxy
4:15pm
8-K
NAMS
NewAmsterdam Pharma Company NV
9 May 24
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
8:00am
10-Q
1y5zuoqy gaqn58j7
8 May 24
Quarterly report
4:30pm
PRE 14A
qjydxxe17p60
29 Apr 24
Preliminary proxy
5:00pm
424B3
8eqrabju z9snix0
19 Apr 24
Prospectus supplement
4:21pm
EFFECT
90ylebb
18 Apr 24
Notice of effectiveness
12:15am
POS AM
musp48
12 Apr 24
Prospectus update (post-effective amendment)
4:15pm
8-K
cdzo6
1 Apr 24
NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer
8:16am
424B3
p46eie xb2
12 Mar 24
Prospectus supplement
4:18pm
EFFECT
71f59t8 39img
11 Mar 24
Notice of effectiveness
12:15am
8-K
5rkv3iyre88o2d
4 Mar 24
Regulation FD Disclosure
8:06am
POS AM
62oey jg2nk
28 Feb 24
Prospectus update (post-effective amendment)
5:01pm
8-K
hucrwac73b88xcj92
28 Feb 24
NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update
8:11am
10-K
tt7ybcqnr3
28 Feb 24
Annual report
8:00am
8-K
jsrx09wkvvnp4bpf
15 Feb 24
NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
4:18pm
424B5
00py2hqugwz e4d3o
15 Feb 24
Prospectus supplement for primary offering
4:15pm
424B5
utnc3
13 Feb 24
Prospectus supplement for primary offering
5:19pm